STAT+: FDA expands Bayer lung cancer drug approval

The FDA expanded its approval of a Bayer lung cancer drug, according to STAT+. The same STAT+ brief notes regulators are working to keep pace with agentic medical AI and that the FDA launched a project to examine why pregnancy registries struggle with enrollment.

Want to stay on top of the science and politics driving biotech today? Sign up https://www.statnews.com/signup/readout/ to get our biotech newsletter in your inbox. Today, we look at how regulators are trying to keep pace with agentic medical AI, see the FDA launch a project to examine why pregnancy registries struggle with enrollment, and more. Someone out there cure asthma, eh? It sucks. This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in /login/ View All Plans https://www.statnews.com/stat-plus/